Skip to content

A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients

A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01871818
Acronym
REHABMUSCLE
Enrollment
240
Registered
2013-06-07
Start date
2013-05-31
Completion date
2017-10-31
Last updated
2018-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple sclerosis, Rehabilitation, Chronic evolutive disease, Physiotherapy, Resistance training, Endurance training

Brief summary

The purpose of this study was to compare the effectiveness of two rehabilitation programs (one month) in patients with multiple sclerosis. The first program is combined with physiotherapy, endurance training and resistance training. The second one is physiotherapy in private practice. Another purpose is to assess the length of the benefits of the combined program.

Detailed description

This study will include 240 patients with a diagnosis of Multiple Sclerosis and with an Expanded Disability Status Scale ≤ 5. Patients will be divided into 2 groups, according to a randomization design. At recruitment (J0), after rehabilitation (M1) and at follow up (M3 and M6) each patient will be tested for the primary and secondary outcomes.

Interventions

BEHAVIORALCombined program

Combined program with physiotherapy, endurance training and resistance training

BEHAVIORALPhysiotherapy in private practice

Physiotherapy in private practice

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 year or over * Able to walk independently without use of assistance 200 meters Expanded Disability Status Scale ≤5 * No relapse within the last three months * No current or recent (six months) participation in intensive rehabilitation * No recent modification (six months) of medications for MS * Patients who received and signed information and informed consent

Exclusion criteria

* Cognitive impairments which could interfere with the ability to fully engage the rehabilitation program. * Recent involvement (three months) in another interventional research study * A complicating medical condition or orthopedic diagnosis that limits rehabilitation * Cardiac or respiratory disease that interfere with endurance training * Patient with safety measure * Pregnant women, breastfeeding * No affiliation to a social security

Design outcomes

Primary

MeasureTime frameDescription
6 Minute Walk Test6 Minutes6 Minute Walk Test (6MWT) at the end of the rehabilitation program (Time Frame : at one month M1)

Secondary

MeasureTime frameDescription
Aerobic capacity1hAerobic capacity (V02 max)
Strength and fatigue of the knee flexors and extensors45 minAssessment of maximal voluntary strength using an isokinetic dynamometer or assessment of maximal voluntary strength using the 1-RM estimation
Functional tests20 MinutesFunctional tests: 10 meters Walk Test, Timed up and go test, Time to ascend and descend stairs, 6 Minute Walk Test Time frame:10 meters walk test = 2 min ; time up and going test= 4 min ; Time to ascend and descend stairs = 4 min ; et 6min walk = 6min
Balance (Berg Balance scale) and postural control assessment15 min
Quality of Life assessment55 minQuality of Life assessed by self-reported questionnaire (SEP -59; EQ-5D), mood (HAD), MSIS-29, auto-questionnaire estimating the fatigue (Fatigue Severity Scale, Modified Fatigue Impact Scale)
Clinical assessment45 minSpasticity assessment (Modified Ashworth Scale), passive range of motion of lower limb joint, lower limb strength (Medical Research Council scale), self questionnaire of pain.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026